KENALOG IN ORABASE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KENALOG IN ORABASE (KENALOG IN ORABASE).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
| Metabolism | Hepatic metabolism primarily via CYP3A4; undergoes reduction, oxidation, and conjugation. |
| Excretion | Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%). |
| Half-life | Terminal half-life approximately 2-5 hours following mucosal application. |
| Protein binding | Approximately 70-90% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | Estimated Vd of 1.5-3.5 L/kg, reflecting extensive tissue distribution. |
| Bioavailability | Systemic bioavailability via oral mucosa is low but not precisely quantified; local delivery is the primary route. |
| Onset of Action | Onset within minutes to hours; clinical effect typically noted 30 minutes after application. |
| Duration of Action | Duration of therapeutic effect is 4-6 hours; mucous membrane adhesion may last 2-3 hours. |
| Molecular Weight | 434.5 |
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
| Dosage form | PASTE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use only if clearly needed and use the smallest effective amount. |
| Geriatric use | Use the smallest effective amount for the shortest duration due to increased potential for systemic effects with age. |
| 1st trimester | Use only if clearly needed; corticosteroids have been associated with oral clefts in some studies, but risk is low. |
| 2nd trimester | Use with caution; no known increased risk of major malformations, but monitor for maternal adrenal suppression. |
| 3rd trimester | Use with caution; prolonged use may suppress fetal adrenal function and cause low birth weight. |
Clinical note
Comprehensive clinical and safety monograph for KENALOG IN ORABASE (KENALOG IN ORABASE).
| Placental transfer | Corticosteroids, including triamcinolone, cross the placenta. The degree of transfer depends on molecular weight and lipophilicity; triamcinolone has moderate transfer. Fetal serum levels may be 10-20% of maternal levels. |
| Breastfeeding | Topical application in the mouth results in minimal systemic absorption; however, caution is advised if applied to large areas. No adverse effects reported in infants. Consider waiting to breastfeed after application. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Known hypersensitivity to triamcinolone or any componentUntreated bacterial, fungal, or viral oral infectionsOcular herpes simplexSystemic fungal infectionsLive or attenuated virus vaccinations (avoid concurrent use)
| Precautions | Immunosuppression may increase susceptibility to infections, Adrenal suppression with prolonged use, Avoid use in patients with known hypersensitivity to corticosteroids, Use with caution in patients with diabetes, hypertension, or osteoporosis, Do not swallow or apply to large areas of skin |
| Food/Dietary | Avoid hot, spicy, or acidic foods during treatment as they may irritate the lesion. No specific food-drug interactions are known. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Triamcinolone acetonide (KENALOG IN ORABASE) is a corticosteroid. Systemic absorption from oral mucosal application is minimal but may occur. In first trimester, corticosteroid use is associated with a small increased risk of oral clefts (odds ratio ~1.3-3.4). Second and third trimester use may cause fetal adrenal suppression, intrauterine growth restriction, and preterm birth if significant systemic exposure occurs. Topical use with minimal absorption is generally considered low risk, but theoretical risks persist. |
| Fetal Monitoring | Monitor for maternal blood pressure, blood glucose, and signs of systemic corticosteroid effects. Fetal growth should be assessed via ultrasound if prolonged use occurs. Neonatal monitoring for adrenal suppression (hypoglycemia, poor feeding) if maternal exposure was extensive near term. |
| Fertility Effects | No direct studies on fertility effects of topical oral corticosteroids. Systemic high-dose corticosteroids may cause menstrual irregularities and reversible ovulatory dysfunction, but at typical doses of KENALOG IN ORABASE, systemic effects are minimal. No adverse effects on male fertility reported. |
| Clinical Pearls | Apply a thin layer to the lesion after meals and at bedtime. Do not rub in; allow to form a film. Avoid use on infected lesions unless antifungal/antibacterial coverage is provided. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease due to potential systemic absorption. |
| Patient Advice | Apply a thin layer to the affected area after meals and at bedtime. · Do not rub or massage the paste into the tissue. · Avoid eating or drinking immediately after application to allow the paste to adhere. · Do not use if you have a fungal or bacterial infection in the mouth unless directed. · Notify your doctor if symptoms persist beyond 7 days or if swelling occurs. |